Ovarian cancer can often appear quietly, with non-specific symptoms, making it difficult to detect at an early stage. Knowing if someone is at an increased risk for ovarian and other cancers can be critical for guiding early detection, prevention, or treatment. Genetic testing can help identify patients with hereditary cancer, allowing for personalized risk counseling and medical management.
OvaNext is designed to give you accurate and clinically meaningful information to help you offer personalized treatment, guide early detection and prevent cancer for patients and their families.
Here are 3 key things you need to know about OvaNext:
- Which genes are included? OvaNext analyzes 25 genes associated with hereditary ovarian, uterine, and breast cancer. Testing genes beyond BRCA1 and BRCA2 can significantly increase detection of patients with hereditary gynecologic cancer.
- Who should be tested? OvaNext is a great tool for patients with a personal or family history suggestive of hereditary gynecologic cancer. Some signs include:
- Young Cancer: Breast or uterine cancer diagnosed at <50y
- Rare Cancer: Ovarian cancer at any age
- Multiple Cancers:
- >2 individuals on the same side of the family with breast, ovarian, uterine, or other cancers
- >2 primary cancers in the same person
- Does this test impact medical management? The majority of genes on OvaNext have published medical management guidelines. In fact, 93% of positive results from OvaNext are clinically actionable.1 With an average turnaround time of 11 days, this test gives you results quickly allowing you to better guide treatment and management.
Learn more about OvaNext here or request additional information from your local Genetic Specialist.
- Namey T et al. Multigene Panel Testing Increases the Detection of Clinically-Actionable Mutations in Ovarian Cancer Patients. Poster Presentation SGO 2018.